In a single-arm, single-institution study, combining pembrolizumab, bevacizumab, and metronomic oral cyclophosphamide led to a median progression-free survival of 10 months in women with recurrent ovarian cancer, with better response in women with platinum-sensitive disease.
Online PARP Inhibitor Education Has Positive Impact on Oncologists’ and OB/GYNs’ Knowledge and Confidence
Although the combination of bevacizumab and olaparib showed superior progression-free survival compared with bevacizumab plus placebo as upfront maintenance therapy in women with advanced ovarian cancer, the lack of an olaparib monotherapy comparator limits meaningful interpretation.
No Difference in Overall Survival Between Nivolumab and Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer
The rate of overall survival was similar between nivolumab and either gemcitabine or pegylated liposomal doxorubicin in the open-label, randomized phase 3 NINJA clinical trial of patients with platinum-resistant ovarian cancer, but the overall duration of response was longer in the nivolumab arm.
Triplet Including Folate Receptor Alpha Antibody–Drug Conjugate Has Activity in Recurrent Ovarian Cancer
Copay Maximizer Programs Replacing Accumulator Programs with Ramifications for Patient Out-of-Pocket Expenses
Trabectedin Added to Pegylated Doxorubicin May Be Viable Treatment for Recurrent Ovarian Cancer But Platinum Remains Standard of Care
The international phase 3 INOVATYON clinical trial did not meet its primary end point of an improvement in overall survival with trabectedin added to pegylated liposomal doxorubicin (PLD) followed by platinum at progression compared with carboplatin plus PLD in patients with recurrent ovarian cancer. Trabectedin plus PLD may still have a role in patients with multiple previous lines of platinum.
NORA Clinical Trial Confirms Efficacy of Individualized Niraparib Starting Dose to Treat Platinum-Sensitive Ovarian Cancer
In the treatment of patients with platinum-sensitive, recurrent ovarian cancer, a lower starting dose of niraparib in patients with a low body weight (77 kg) or low platelet count (150,000/μL) had similar efficacy as the fixed 300-mg starting dose versus placebo on the end point of progression-free survival, confirming a previous observation.
Page 4 of 10
Results 31 - 40 of 93
Results 31 - 40 of 93